WP1130 has been shown to increase the sensitivity of cancer cells, such as hepatocellular carcinoma cells, breast cancer cells, and pancreatic cancer cells, to chemotherapeutic agents by inhibiting USP9X activity (58–60), although no relevant clinical trials have been reported to date. Here, USP9X is linked to familial pancreatic carcinoma.